Progesterone Receptor Quantification as a Strong Prognostic Determinant in Postmenopausal Breast Cancer Women under Tamoxifen Therapy
暂无分享,去创建一个
Andrew Kramar | Pierre-Jean Lamy | Philippe Rouanet | P. Rouanet | P. Lamy | P. Pujol | A. Kramar | J. Grenier | S. Thézénas | Pascal Pujol | Simon Thezenas | Françoise Guilleux | Jean Grenier | F. Guilleux
[1] D. Allred,et al. Estrogen receptor status (ER) determined by immunohistochemistry (IHC) is superior to biochemical ligand-binding (LB) assay for evaluating breast cancer patients , 1997 .
[2] J. Daurès,et al. Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause , 1998, Cancer.
[3] W. McGuire,et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] W. McGuire,et al. The value of estrogen and progesterone receptors in the treatment of breast cancer , 1980, Cancer.
[5] G M Clark,et al. Steroid receptors and other prognostic factors in primary breast cancer. , 1988, Seminars in oncology.
[6] J. V. Von Roenn,et al. Quantitative estrogen and progesterone receptor levels related to progression-free interval in advanced breast cancer patients treated with megestrol acetate or tamoxifen. , 1988, Seminars in oncology.
[7] I. Christensen,et al. Short recurrence-free survival associated with high oestrogen receptor levels in the natural history of postmenopausal, primary breast cancer. , 1993, European journal of cancer.
[8] A. D. Schryver,et al. Systemic treatment of early breast-cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women: 1 , 1992 .
[9] J. Elwood,et al. Oestrogen receptors in breast tumours: associations with age, menopausal status and epidemiological and clinical features in 735 patients. , 1980, British Journal of Cancer.
[10] Earlybreastcancertrialistscol,et al. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992, The Lancet.
[11] R. Simon,et al. Flexible regression models with cubic splines. , 1989, Statistics in medicine.
[12] R. Rubens,et al. Estrogen and progesterone receptors: Correlation of response rates, site and timing of receptor analysis , 1982, Breast cancer research and treatment.
[13] A. Forsberg,et al. Menopausal status and cut off levels of steroid receptor ligand binding assays in breast cancer. , 1989, Anticancer research.
[14] Mike Clarke,et al. Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.
[15] G. Contesso,et al. Is the negative prognostic value of high oestrogen receptor (ER) levels in postmenopausal breast cancer patients due to a modified ER gene product? , 1995, European journal of cancer.
[16] O. H. Lowry,et al. Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.
[17] Mike Clarke,et al. Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.
[18] Anthony Howell,et al. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. , 1992 .
[19] J. Raemaekers,et al. Progesterone receptor activity and relapse-free survival in patients with primary breast cancer: The role of adjuvant chemotherapy , 1988, Breast Cancer Research and Treatment.
[20] G. Leclercq,et al. Estrogen receptors in human breast cancer. , 1973, European Journal of Cancer.
[21] D. Coradini,et al. Relationship between Steroid Receptors (As Continuous Variables) and Response to Adjuvant Treatments in Postmenopausal Women with Node-Positive Breast Cancer , 1999, The International journal of biological markers.
[22] M. Lippman,et al. The effects of androgens and antiandrogens on hormone-responsive human breast cancer in long-term tissue culture. , 1976, Cancer research.
[23] W. McGuire,et al. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen , 2004, Breast Cancer Research and Treatment.
[24] S. Korenman. Comparative binding affinity of estrogens and its relation to estrogenic potency. , 1969, Steroids.
[25] B. Rasmussen,et al. BENEFICIAL EFFECT OF ADJUVANT TAMOXIFEN THERAPY IN PRIMARY BREAST CANCER PATIENTS WITH HIGH OESTROGEN RECEPTOR VALUES , 1985, The Lancet.
[26] M. Fernö,et al. Recurrence-free survival in breast cancer improved by adjuvant tamoxifen -especially for progesterone receptor positive tumors with a high proliferation , 2004, Breast Cancer Research and Treatment.
[27] E. J. Gregory,et al. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. , 1977, Cancer research.
[28] W. McGuire. Estrogen receptors in human breast cancer. , 1973, The Journal of clinical investigation.